This pipeline is loaded with potential. Drug development is not easy nor any guarantees, however, premier candidates that have superior peclinical results or get through initial human clinicials hold significant value. There are 3 platforms here that exhibit plenty of early success. It then becomes important to realize that value to provide flexibility and resources to smoothly transition these candidates into intermediate and later stage development cycles.
At least thats what I think stakeholders and investors like retail on this forum are hoping for.